Memorial Sloan-Kettering Cancer Center Sleepy Hollow: Clinical Trials at Sleepy Hollow

Browse our continually updated listing of clinical trials available to patients at Memorial Sloan-Kettering Cancer Center Sleepy Hollow below. You can also explore our complete listing of clinical trials available at Memorial Sloan-Kettering.

Showing 1 - 20 of 75 trials
Title Investigatorsort icon Disease(s)
A Phase II Study of Neoadjuvant Dose-Dense Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer
[Protocol 12-071] 		Bajorin, Dean
  • Bladder Cancer
A Phase II Study of Gemcitabine and Pazopanib in Previously Untreated Patients with Advanced Urothelial Cancers Who Cannot Receive Cisplatin
[Protocol 11-191] 		Bajorin, Dean
  • Bladder Cancer
  • Kidney Cancer
A Genotype-Phenotype Urothelial Cancer Study
[Protocol 09-025] 		Bajorin, Dean
  • Bladder Cancer
  • Hereditary Cancer & Genetics
Surviving Oropharynx Cancer: Long-Term Impact of Human Papillomavirus on Quality of Life
[Protocol 10-111] 		Baxi, Shrujal
  • Head & Neck Cancer
  • Survivorship
Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life
[Protocol 10-071] 		Blinder, Victoria
  • Breast Cancer
  • Survivorship
A Phase II Study of mFOLFOX6 with Bevacizumab or Tivozanib in Patients with Metastatic Colorectal Cancer
[Protocol 12-066] 		Cercek, Andrea
  • Colorectal Cancer
    • Colon Cancer
A Phase II Study of Neoadjuvant Pemetrexed Plus Cisplatin for Patients with Resectable Non-Squamous Non-Small Cell Lung Cancer with "Switch Chemotherapy Alternative" in Non-Responders (NEOSCAN)
[Protocol 11-106] 		Chaft, Jamie
  • Lung Cancer
  • Lung Cancer, Non-Small Cell
    • Lung Adenocarcinoma
A Phase I Study of Afatinib with Chemotherapy and Radiation Therapy in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
[Protocol 12-279] 		Chaft, Jamie
  • Lung Cancer, Non-Small Cell
Molecular Mechanisms of Clinical Resistance to Anti-HER2 Therapy Among Patients with HER2-Amplified Breast Cancer
[Protocol 06-163] 		Chandarlapaty, Sarat
  • Breast Cancer
A Phase I/II Clinical Trial of Temsirolimus plus Neratinib for Patients with Metastatic HER2-Amplified or Triple-Negative Breast Cancer
[Protocol 10-005] 		Chandarlapaty, Sarat
  • Breast Cancer
A Phase II Study of Secondary Cytoreduction with and without HIPEC plus Postoperative Chemotherapy for Women with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
[Protocol 12-275] 		Chi, Dennis
  • Ovarian Cancer
A Phase II Study of Gemcitabine and Cisplatin before Surgery in Patients with High-Grade Upper Tract Urothelial Carcinoma
[Protocol 10-208] 		Coleman, Jonathan
  • Kidney Cancer
A Phase III Study of Chemotherapy and Trastuzumab with or without Pertuzumab in Patients with Operable HER2-Positive Breast Cancer
[Protocol 12-115] 		Dang, Chau
  • Breast Cancer
A Study Assessing the Feasibility of Treatment with Paclitaxel, Trastuzumab, and Lapatinib in Women with HER2-Positive Early-Stage Breast Cancer
[Protocol 13-002] 		Dang, Chau
  • Breast Cancer
A Phase II Study of Paclitaxel, Trastuzumab, and Pertuzumab for the Treatment of Metastatic HER2-Positive Breast Cancer
[Protocol 10-142] 		Dang, Chau
  • Breast Cancer
A Phase II Study of Fulvestrant Alone or with GDC-0941 or GDC-0980 in Women with Advanced Breast Cancer Resistant to Aromatase Inhibitor Therapy
[Protocol 12-029] 		Dickler, Maura
  • Breast Cancer
A Phase II Study of Adjuvant Bevacizumab, Metronomic Chemotherapy, Diet, and Exercise After Preoperative Chemotherapy for Breast Cancer
[Protocol 11-063] 		Dickler, Maura
  • Breast Cancer
A Phase III Study of BKM120 with Fulvestrant in Postmenopausal Women with Locally Advanced or Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
[Protocol 12-290] 		Dickler, Maura
  • Breast Cancer
A Phase II Study of MLN8237 in Advanced or Metastatic Sarcoma
[Protocol 12-194] 		Dickson, Mark
  • Sarcomas
    • Soft Tissue Sarcoma
A Phase II Trial of Bevacizumab, Cetuximab, Cisplatin, and Intensity-Modulated Radiation Therapy for Patients with Stage III/IV Head and Neck Squamous Cell Carcinoma
[Protocol 09-083] 		Fury, Matthew
  • Head & Neck Cancer